干扰素治疗慢性乙型肝炎病毒感染的经济效益

目的:评估慢性乙型肝炎及其并发症的经济负担和α-干扰素(IFN-α)治疗的临床效果与经济效益。方法:根据慢性乙型肝炎、代偿性肝硬化、失代偿性肝硬化和肝癌患者的年直接医疗费用、非直接医疗费用以及间接费用,计算其经济负担。同时,根据IFN-α+常规治疗和常规治疗2种方案所得的临床治疗结果,计算IFN-α治疗节省的费用。结果:不同肝病阶段的患者年直接医疗费用、年经济负担不同,慢性乙型肝炎为9000、11362元,代偿性肝硬化为13865、19412元,失代偿性肝硬化为25678、36979元,肝癌为26501、40264元。IFN-α+常规治疗方法治疗慢性乙型肝炎患者4mo,随访5y,与常规治疗比较,其直接医疗费用、总费用得到节省,节省金额分别为831元/人、2038元/人;其存活率可提高2·8%。结论:慢性乙型肝炎病毒感染者经济负担较重,而采用IFN-α治疗则可降低其经济负担。

Economic Benefit of Interferon in Treatment of Chronic Hepatitis B Virus Infection

OBJECTIVE:To evaluate the economic burden of chronic hepatitis B(CHB)and its complications,and to e-valuate the benefits of treatment with interferon-α.METHODS:The components of the economic burden of disease included direct medical costs and non-medical costs as well as indirect economic loss per patient-year in patients with chronic hepatitis B virus infections,including chronic hepatitis B,compensated and decompensated cirrhosis,and hepatocellular carcinoma.Net cost savings due to treatment of CHB with interferon-αwere estimated using clinical data from2therapeutic schemes used in hospital.RESULTS:For the patients at different stages of hepatopathy,the direct medical cost and economic burden per year were different:9000yuan,11362yuan(CHB);13865yuan,19412yuan(compensated cirehosis);25678yuan,36979yuan(decompensated cirrhosis);26501yuan,40264yuan(liver cancer),Compared with conrentional therapy against CHB,the direct medical cost and total cost were reduced following4months treatment of interferon-αafter5-year follow-up.The reduced amounts were831yuan,2038yuan per person,respectively.The surrival rate rised by2.8%.CONCLUSION:CHB infections create a heavy economic burden on the society,as well as patients and their families.We have seen the potential cost-savings due to treatment with interferon-α.